Photo of Khanh T Do,  MD

Khanh T Do, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-6992
Fax: (617) 632-2630

Khanh T Do, MD

Dana-Farber Cancer Institute


  • Clinical Instructor, Medicine, Harvard Medical School
  • Instructor, Medical Oncology, Dana-Farber Cancer Institute


Research Abstract

After completing my fellowship in Medical Oncology and Hematology at the National Cancer Institute, National Institutes of Health in 2013, I pursued further drug development training in the Advanced Developmental Therapeutics Training Program (ADTTP) of the Division of Cancer Treatment and Diagnosis, National Cancer Institute. My training in this program exposed me to the various aspects of protocol development, the principles of biomarker development and incorporation of biomarkers that demonstrate proof-of-mechanism and target engagement in clinical trials. I interacted closely with the translational laboratories and investigators at the Cancer Therapy and Evaluation Program, NCI, to translate laboratory data into the clinic and to incorporate correlative studies in my clinical protocols. I was the lead associate investigator for a Phase 1 study of the first-in-class inhibitor of the WEE1 kinase, AZD1775 which was selected for oral presentation at the 2014 Annual Meeting of ASCO and for which I received a Merit Award. The results of this study have since been published in the Journal of Clinical Oncology. As part of this study, I also collaborated extensively with the Laboratory for Tumor Immunology and Biology, and coordinated the collection of patient blood samples for evaluation of markers of immune-mediated tumor lysis.

As part of my current appointment in the Early Drug Development Center (EDDC), Dana-Farber Cancer Institute, I am currently a co-investigator on several studies and am the Principal Investigator for an Investigator-initiated study of prexasertib, CHK1 inhibitor, in combination with olaparib, PARP inhibitor.


Powered by Harvard Catalyst
  • Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 2016; 1:e87062. PubMed
  • Kummar S, Do K, Coyne GO, Chen A, Ji J, Rubinstein L, Doroshow JH. Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Semin Oncol 2016; 43:446-52. PubMed
  • Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen AP, Doroshow JH, Kummar S. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol 2015; 33:3409-15. PubMed
  • Do K, O'Sullivan Coyne G, Chen AP. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol 2015; 4:31. PubMed
  • Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S. A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clin Colorectal Cancer 2015; 14:154-61. PubMed
  • Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummar S. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs 2015; 33:921-30. PubMed
  • Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datiles M, Eugeni M, Lam MH, Doyle LA, Doroshow JH, Kummar S. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest New Drugs 2015; 33:720-8. PubMed
  • Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013; 12:3159-64. PubMed